Press-release for stocks for cellectis s.a.

Prices are updated after-hours

entities : Cellectis s.a. crawled time : 22:00

save search

Monthly information on share capital and company voting rights
Published: 2024-03-04 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 0.77% | O: -3.08% H: 1.59% C: -1.59%
company

Monthly information on share capital and company voting rights
Published: 2024-02-02 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist
company

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
Published: 2024-01-16 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| -5.42% | O: -3.97% H: 1.88% C: -1.5%
million agreement

Monthly information on share capital and company voting rights
Published: 2024-01-08 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| -12.96% | O: -3.32% H: 3.09% C: 2.06%
company

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
Published: 2023-12-22 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist
ORTX | $16.7 0.0% 370K

Health Technology

| Email alert Add to watchlist
meeting results

Monthly information on share capital and company voting rights
Published: 2023-12-01 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist
company

Cellectis’ Shareholders Meeting to be Held on December 22, 2023
Published: 2023-11-17 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist
meeting

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
Published: 2023-04-04 (Crawled : 22:00) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 30.35% | O: -0.5% H: 1.0% C: -1.5%
agreement

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 32.32% | O: -3.54% H: 2.09% C: -4.19%
talen research meeting breast association presentation cancer negative

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-03-08 (Crawled : 22:00) - globenewswire.com
RLAY | $6.34 7.46% 6.94% 1.7M

Health Technology

| -65.11% | O: -0.41% H: 1.78% C: -7.54%
IOVA 4 | $11.69 -1.43% -1.45% 2.7M

Health Technology

| 70.89% | O: 0.29% H: 0.72% C: -6.75%
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 21.3% | O: -2.78% H: 0.95% C: -1.19%
year financial update results

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
Published: 2023-03-06 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 21.3% | O: 0.93% H: 0.92% C: -0.92%
financial update results

Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
Published: 2023-03-01 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 19.09% | O: 0.91% H: 2.25% C: -3.83%
report financial

Monthly information on share capital and company voting rights
Published: 2023-02-09 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 18.55% | O: 7.69% H: 1.9% C: -2.1%

Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
Published: 2023-01-20 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist
collaboration therapeutics agreement

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases
Published: 2022-12-29 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 34.36% | O: -2.56% H: 11.05% C: 10.53%
collaboration platform

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities
Published: 2022-12-28 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 41.62% | O: 4.86% H: 7.22% C: 0.52%
innovation

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
Published: 2022-12-22 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 32.99% | O: 8.12% H: 0.0% C: -6.57%
ucart22 treatment candidate

Monthly information on share capital and company voting rights
Published: 2022-12-16 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| Email alert Add to watchlist

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
Published: 2022-12-01 (Crawled : 22:00) - globenewswire.com
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 20.18% | O: -0.92% H: 2.78% C: 0.93%
update

Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
Published: 2022-09-28 (Crawled : 22:00) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K

Health Technology

| 10.08% | O: -0.84% H: 5.93% C: 2.97%